Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

NCT00433095 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.

NCT NCT00433095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00433095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
Lead sponsor
Ludwig-Maximilians - University of Munich
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma breast stage iv